TRVN

Trevena, Inc. (TRVN) | Rumor.io

Trevena

TRVN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TRVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 7

Trevena, Inc. ($TRVN) received a Nasdaq delisting notification due to low stock price and is facing potential delisting.
The company's stock has been subject to criticism and negative sentiment from investors, with some accusing it of being a "front for dilution and raises to fund salaries".
Trevena's stock price has been volatile, with some investors expressing disappointment and frustration with the company's performance, particularly in light of its failed FDA-approved drug.

Generated by AI

Sentiment

Of the messages about TRVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	48.57% -9.04
Bearish	—	—	—	51.43% +9.04

Bullish· Sep 10

$TRVN has seen a significant price increase, reaching $7.50 after a mention at $4.80, indicating strong momentum.
Analysts are bullish on $TRVN, with two predicting a minimum price of $12.50, suggesting a strong potential for future growth.
$TRVN's small float and undervalued/oversold status make it a high-risk, high-reward stock that could experience significant price volatility in the near future.

Bearish· Jun 20

The market has been heavily shorted, with unlimited shares available for shorting.
The company's management has been criticized for its performance, with some suggesting it is incompetent.
The SEC's decision to grant the company an extension to trade on NASDAQ has been seen as a failure to protect retail investors.

Generated by AI

Topics

Of the messages about TRVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	0%
Controversies	—	—	—	100%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· May 6

Trevena, Inc. reported first quarter 2021 earnings of -$0.06 EPS, beating consensus estimates by $0.02.
The company's revenue of $0.21M missed Estimize revenue consensus by $0.48M.
Trevena's first quarter was not as bad as expected, but the company's high burn rate and need for new cash are major concerns.

Analysts· Oct 10

JMP Securities analyst Jason Butler reiterated a Market Outperform rating and $15 price target for $TRVN.
Jefferies downgraded $TRVN to Hold from Buy with a price target of $1 from $10.
Analyst Biren Amin at Jefferies has reiterated a BUY rating on $TRVN 15 times since Feb 2014.

Announcements· Sep 6

Trevena, Inc. ($TRVN) received a $15 million non-dilutive tranche, leading to a significant stock price increase.
The company announced preliminary positive data from two proof-of-concept studies evaluating TRV045's mechanism of action and CNS target engagement.
JMP Securities reiterated a Buy rating on Trevena with a price target of $4.00, citing the company's potential for growth.

Controversies· Aug 8

Trevena, Inc.'s (TRVN) Olinvyk opioid has been approved by the FDA for intravenous use in hospitals and other controlled clinical settings.
The approval comes as a significant development in the pharmaceutical industry, with some experts questioning the effectiveness of Olinvyk compared to morphine.
The FDA's approval of Olinvyk has been met with a mix of reactions, with some investors optimistic about the potential for growth and others expressing concerns about the opioid crisis.

Technical Analysis· May 9

$TRVN has shown potential for an inside bar play, with a confirmed break over $2.77 and $3.2 required for a meaningful move.
The stock has major support at $2.31-$2.42, and a break above $4.15 could lead to a price of $5.5.
The 200-day moving average is currently at $2.89, and a previous crossing of this level led to significant price movement, including FDA approval on August 10th, 2020.

Generated by AI

Community

Of the messages about TRVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	65.43%
Newcomers	—	—	—	34.57%

Regulars· Jun 20

Trevena's TRV045 has shown promise in preclinical trials, with statistically significant anti-seizure activity in epilepsy models and a novel mechanism of analgesic effect in chronic neuropathic pain models.
The company's float rotation has increased volatility, with a high volume of trades and a significant percentage of shares being traded, indicating a potential shift in market sentiment.
Trevena's stock has been negatively impacted by the announcement of preliminary preclinical data showing that TRV045 did not show a statistically significant effect in a model of how epilepsy develops, leading to a decline in stock price.

Newcomers· Sep 6

Newcomers to the $TRVN micro trend are warned to be cautious of the asset's volatile nature, with some experiencing "wicked fast and dangerous" losses if they don't keep a close eye on the macro trends.
The recent news of Trevena, Inc. ($TRVN) receiving a $15 million non-dilutive tranche and announcing positive preliminary data from proof-of-concept studies have contributed to the asset's significant price increase, with some users noting a 38% premarket surge.
Some users are cautious about $TRVN's chart pattern, noting that it resembles that of another asset ($VERB) and that volume in the premarket is 5 million, which could impact the asset's performance at the open.

Generated by AI

Also Discussed

Investors talking about TRVN also mention

#	Name	Attention
1	Lipocine Inc.LPCN	0%new
2	CorMedix Inc.CRMD	0%+0
3	Talphera, Inc.TLPH	0%0
4	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
5	Verastem Inc.VSTM	0%0
6	Fennec Pharmaceuticals Inc.FENC	0%0
7	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
8	PRTK - Paratek Pharmaceuticals, Inc.	——
9	ASXC - Asensus Surgical, Inc.	——
10	RGLS - Regulus Therapeutics Inc.	——

Trevena, Inc.

Location

Social

What share of all stock conversation is about TRVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 7

Trevena, Inc. ($TRVN) received a Nasdaq delisting notification due to low stock price and is facing potential delisting.
The company's stock has been subject to criticism and negative sentiment from investors, with some accusing it of being a "front for dilution and raises to fund salaries".
Trevena's stock price has been volatile, with some investors expressing disappointment and frustration with the company's performance, particularly in light of its failed FDA-approved drug.

Generated by AI

Sentiment

Of the messages about TRVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	48.57% -9.04
Bearish	—	—	—	51.43% +9.04

Bullish· Sep 10

$TRVN has seen a significant price increase, reaching $7.50 after a mention at $4.80, indicating strong momentum.
Analysts are bullish on $TRVN, with two predicting a minimum price of $12.50, suggesting a strong potential for future growth.
$TRVN's small float and undervalued/oversold status make it a high-risk, high-reward stock that could experience significant price volatility in the near future.

Bearish· Jun 20

The market has been heavily shorted, with unlimited shares available for shorting.
The company's management has been criticized for its performance, with some suggesting it is incompetent.
The SEC's decision to grant the company an extension to trade on NASDAQ has been seen as a failure to protect retail investors.

Generated by AI

Topics

Of the messages about TRVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	0%
Controversies	—	—	—	100%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· May 6

Trevena, Inc. reported first quarter 2021 earnings of -$0.06 EPS, beating consensus estimates by $0.02.
The company's revenue of $0.21M missed Estimize revenue consensus by $0.48M.
Trevena's first quarter was not as bad as expected, but the company's high burn rate and need for new cash are major concerns.

Analysts· Oct 10

JMP Securities analyst Jason Butler reiterated a Market Outperform rating and $15 price target for $TRVN.
Jefferies downgraded $TRVN to Hold from Buy with a price target of $1 from $10.
Analyst Biren Amin at Jefferies has reiterated a BUY rating on $TRVN 15 times since Feb 2014.

Announcements· Sep 6

Trevena, Inc. ($TRVN) received a $15 million non-dilutive tranche, leading to a significant stock price increase.
The company announced preliminary positive data from two proof-of-concept studies evaluating TRV045's mechanism of action and CNS target engagement.
JMP Securities reiterated a Buy rating on Trevena with a price target of $4.00, citing the company's potential for growth.

Controversies· Aug 8

Trevena, Inc.'s (TRVN) Olinvyk opioid has been approved by the FDA for intravenous use in hospitals and other controlled clinical settings.
The approval comes as a significant development in the pharmaceutical industry, with some experts questioning the effectiveness of Olinvyk compared to morphine.
The FDA's approval of Olinvyk has been met with a mix of reactions, with some investors optimistic about the potential for growth and others expressing concerns about the opioid crisis.

Technical Analysis· May 9

$TRVN has shown potential for an inside bar play, with a confirmed break over $2.77 and $3.2 required for a meaningful move.
The stock has major support at $2.31-$2.42, and a break above $4.15 could lead to a price of $5.5.
The 200-day moving average is currently at $2.89, and a previous crossing of this level led to significant price movement, including FDA approval on August 10th, 2020.

Generated by AI

Community

Of the messages about TRVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	65.43%
Newcomers	—	—	—	34.57%

Regulars· Jun 20

Trevena's TRV045 has shown promise in preclinical trials, with statistically significant anti-seizure activity in epilepsy models and a novel mechanism of analgesic effect in chronic neuropathic pain models.
The company's float rotation has increased volatility, with a high volume of trades and a significant percentage of shares being traded, indicating a potential shift in market sentiment.
Trevena's stock has been negatively impacted by the announcement of preliminary preclinical data showing that TRV045 did not show a statistically significant effect in a model of how epilepsy develops, leading to a decline in stock price.

Newcomers· Sep 6

Newcomers to the $TRVN micro trend are warned to be cautious of the asset's volatile nature, with some experiencing "wicked fast and dangerous" losses if they don't keep a close eye on the macro trends.
The recent news of Trevena, Inc. ($TRVN) receiving a $15 million non-dilutive tranche and announcing positive preliminary data from proof-of-concept studies have contributed to the asset's significant price increase, with some users noting a 38% premarket surge.
Some users are cautious about $TRVN's chart pattern, noting that it resembles that of another asset ($VERB) and that volume in the premarket is 5 million, which could impact the asset's performance at the open.

Generated by AI

Trevena

Social

Oct 7

Sentiment

Bullish· Sep 10

Bearish· Jun 20

Topics

Earnings· May 6

Analysts· Oct 10

Announcements· Sep 6

Controversies· Aug 8

Technical Analysis· May 9

Community

Regulars· Jun 20

Newcomers· Sep 6

Also Discussed

Trevena, Inc.

Company Information

Location

Also Discussed

Social

Oct 7

Sentiment

Bullish· Sep 10

Bearish· Jun 20

Topics

Earnings· May 6

Analysts· Oct 10

Announcements· Sep 6

Controversies· Aug 8

Technical Analysis· May 9

Community

Regulars· Jun 20

Newcomers· Sep 6